Epidemiology, clinical characteristics, and antimicrobial susceptibility profiles of human clinical isolates of Staphylococcus intermedius group by Yarbrough, Melanie L et al.




Epidemiology, clinical characteristics, and
antimicrobial susceptibility profiles of human
clinical isolates of Staphylococcus intermedius
group
Melanie L. Yarbrough
Washington University School of Medicine in St. Louis
William Lainhart
Washington University School of Medicine in St. Louis
Carey-Ann D. Burnham
Washington University School of Medicine in St. Louis
Follow this and additional works at: https://digitalcommons.wustl.edu/open_access_pubs
This Open Access Publication is brought to you for free and open access by Digital Commons@Becker. It has been accepted for inclusion in Open
Access Publications by an authorized administrator of Digital Commons@Becker. For more information, please contact engeszer@wustl.edu.
Recommended Citation
Yarbrough, Melanie L.; Lainhart, William; and Burnham, Carey-Ann D., ,"Epidemiology, clinical characteristics, and antimicrobial
susceptibility profiles of human clinical isolates of Staphylococcus intermedius group." Journal of Clinical Microbiology.56,3.
e01788-17. (2018).
https://digitalcommons.wustl.edu/open_access_pubs/6632
Epidemiology, Clinical Characteristics, and Antimicrobial
Susceptibility Proﬁles of Human Clinical Isolates of
Staphylococcus intermedius Group
Melanie L. Yarbrough,a William Lainhart,a Carey-Ann D. Burnhama
aDepartment of Pathology & Immunology, Division of Laboratory and Genomic Medicine, Washington
University School of Medicine, St. Louis, Missouri, USA
ABSTRACT The veterinary pathogens in the Staphylococcus intermedius group (SIG)
are increasingly recognized as causes of human infection. Shared features between
SIG and Staphylococcus aureus may result in the misidentiﬁcation of SIG in human
clinical cultures. This study examined the clinical and microbiological characteristics
of isolates recovered at a tertiary-care academic medical center. From 2013 to 2015,
81 SIG isolates were recovered from 62 patients. Patients were commonly 50 years
old, diabetic, and/or immunocompromised. Documentation of dog exposure in the
electronic medical record was not common. Of the 81 SIG isolates, common sites of
isolation included 37 (46%) isolates from wound cultures and 17 (21%) isolates from
respiratory specimens. Although less common, 10 (12%) bloodstream infections were
documented in 7 unique patients. The majority of SIG (65%) isolates were ob-
tained from polymicrobial cultures. In comparison to S. aureus isolates from the
same time period, signiﬁcant differences were noted in proportion of SIG isolates
that were susceptible to doxycycline (74% versus 97%, respectively; P  0.001),
trimethoprim-sulfamethoxazole (65% versus 97%, respectively; P  0.001), and cipro-
ﬂoxacin (78% versus 59%, respectively; P  0.01). Methicillin resistance (MR) was de-
tected in 12 (15%) of 81 SIG isolates. All MR isolates detected by an oxacillin disk
diffusion test would have been misclassiﬁed as methicillin susceptible using a cefoxi-
tin disk diffusion test. Thus, SIG is recovered from human clinical specimens, and dis-
tinction of SIG from S. aureus is critical for the accurate characterization of MR status
in these isolates.
KEYWORDS Staphylococcus intermedius group, Staphylococcus pseudintermedius,
mecA, methicillin resistance
Members of the Staphylococcus intermedius group (SIG) are commonly recoveredfrom clinical specimens from animals. However, SIG strains are also associated
with serious human infections. Recent advancements in bacterial identiﬁcation meth-
ods, such as matrix-assisted laser desorption ionization–time of ﬂight mass spectrom-
etry (MALDI-TOF MS), have led to the observation that members of the SIG are
increasingly isolated from human clinical specimens (1).
The SIG consists of S. pseudintermedius, S. intermedius, and S. delphini. These organ-
isms are zoonotic pathogens that commonly colonize the mucosal surfaces of animals,
particularly dogs (2). SIG strains are associated with skin and soft tissue infections, as
well as invasive infections in animals. Previously, human infections caused by SIG strains
were thought to be associated with animal contact, such as dog bites (3, 4). However,
a recent investigation of SIG isolates obtained from 39 patients found an association
with dogs in only 10% of cases (1). Prior reports have implicated SIG isolates in a variety
of morbidities, including pneumonia, skin and soft tissue infections, hardware infec-
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tions, and bacteremia (1, 4–6), but the epidemiology and clinical features of these
infections have thus far not been extensively described.
In the past, phenotypic and biochemical proﬁling may have mistakenly identiﬁed
SIG as Staphylococcus aureus, as both are coagulase-positive catalase-positive Gram-
positive cocci that exhibit beta-hemolysis on blood agar plates (7, 8). Thus, the true
incidence of the SIG as a cause of human infection may be underestimated. The
performance of MALDI-TOF MS for the identiﬁcation of SIG isolates has been evaluated,
and while species-level identiﬁcation within the complex is not well characterized,
these studies support the idea that MALDI-TOF MS can accurately identify SIG isolates
to a group level (9, 10).
Like S. aureus, SIG isolates can acquire methicillin resistance (MR) via expression of
the mecA gene (11). The incidence of methicillin-resistant SIG isolates is increasing in
veterinary clinical specimens (12, 13). Notably, prediction of MR in the SIG is most
accurate using oxacillin as a surrogate for MR (14), and antimicrobial susceptibility
testing (AST) standards have now been updated to reﬂect this detail (15, 16). For this
reason, distinction from S. aureus is important, because cefoxitin is the recommended
surrogate for resistance in S. aureus (15). In one recent study, the use of a cefoxitin disk
diffusion test to predict MR in SIG resulted in very major error rates of 29.7% and 75.7%
using coagulase-negative Staphylococcus (CNS) and S. aureus breakpoints, respectively
(14). Conversely, there were no very major errors using an oxacillin disk diffusion test
in combination with the S. pseudintermedius criteria from the CLSI VET01-S2 standards
(14, 37), and standards for human AST are updated to reﬂect this (15). Thus, proper
differentiation of the SIG from S. aureus is necessary to ensure accurate AST and
facilitate appropriate therapy.
The objective of this study was to describe the epidemiology and clinical charac-
teristics of SIG strains recovered from human clinical specimens. SIG isolates obtained
as part of routine clinical care at a 1,250-bed tertiary-care academic medical center from
2013 to 2015 were retrospectively analyzed to deﬁne the salient characteristics sur-
rounding each isolate. In addition, the antimicrobial susceptibility proﬁles were ana-
lyzed and compared to the institutional S. aureus antibiogram. To our knowledge, this
is the largest study to date characterizing the epidemiology of human SIG infection.
(Preliminary results from this study were presented at the American Society for
Microbiology Microbe Conference, 1 to 5 June 2017, New Orleans, LA, USA.)
MATERIALS AND METHODS
Isolate and subject characteristics. Following approval from the Washington University in St. Louis
institutional review board, a retrospective analysis was performed on all SIG strains isolated (n 81) from
clinical specimens from adult patients (18 years of age) submitted to the microbiology laboratory of a
1,250-bed tertiary-care hospital between 2013 and 2015. All isolates were identiﬁed and reported
according to standard-of-care procedures at the time of isolation. The laboratory information system was
queried for the microbiologic characteristics of each specimen, including source, colony morphology,
biochemical testing results, Gram stain description, method of identiﬁcation, number and type of
microorganisms in polymicrobial cultures, and antimicrobial susceptibility testing results. Demographic
and clinical data were obtained through chart reviews of 62 individual subjects included in the study. To
compare the seasonality of SIG infections, the average temperature of the St. Louis area was compared
to the number of SIG strains isolated in each quarter of 2013 to 2015. Average temperatures were pulled
from data archived online (see https://www.weather.gov/media/lsx/climate/stl/temp/temp_stl_monthly
_seasonal_averages.pdf).
Identiﬁcation methods. SIG isolates were identiﬁed either by phenotypic testing or MALDI-TOF MS
using the Bruker Biotyper (Bruker Daltonics, Billerica, MA), according to the standard operating proce-
dures of the laboratory at the time an isolate was recovered. The Bruker Biotyper software versions in use
over the course of the study included 3.1, 4.0, and 5.0. Phenotypic testing included coagulase, catalase,
pyrrolidonyl arylamidase (PYR; Thermo Scientiﬁc/Oxoid, Waltham, MA), and Staphylococcus latex agglu-
tination (StaphTEX; Hardy Diagnostics, Santa Maria, CA) testing. Alternatively, isolates were phenotypi-
cally identiﬁed using the Vitek 2 system with Gram-positive ID (GPID) cards (bioMérieux, St. Louis, MO).
Antimicrobial susceptibility testing. All SIG isolates were routinely tested for antimicrobial suscep-
tibility using the Vitek 2 system or Kirby-Bauer disk diffusion test performed on Mueller-Hinton agar (BD,
Franklin Lakes, NJ). AST on the Vitek 2 system was performed using the GP70 card, according to the
manufacturer’s recommendations. Testing was performed and interpreted according to CLSI standards
(15, 18). Prior to the recommendation that oxacillin be used as a surrogate for methicillin resistance in
SIG isolates, cefoxitin was used as a surrogate and interpreted according to the coagulase-negative
Yarbrough et al. Journal of Clinical Microbiology
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Staphylococcus breakpoints (19). The susceptibility testing results were compared to the 2015 Staphylo-
coccus aureus antibiogram that was produced in accordance with CLSI guidelines (20). Penicillin-binding
protein 2a (PBP2a) was tested using a rapid immunochromatographic assay according to the manufac-
turer’s instructions (PBP2a culture colony test; Alere, Waltham, MA).
Statistical analysis. Fisher’s exact test and linear regression analyses were performed in R (version
3.3.1).
RESULTS
Epidemiology of human SIG infections. A total of 81 SIG isolates from 62 unique
patients recovered from 2013 to 2015 were included in the analysis. A total of 32 (52%)
patients were male, and the overall median age was 58 years (interquartile range [IQR],
45.3 to 63.8 years) (Table 1). In comparison, 55% of patients with either S. aureus (n 
2,655) or CNS (n  1,537) isolated in culture from our laboratory during the same time
period were male (P  0.83) (21). The majority of patients (n  32 [52%]) with SIG
infection were between the ages of 50 and 69 years old, in comparison to 46% of






















Cystic ﬁbrosis 1 (6)
Hardware 18 (29)
Central catheter 11 (61)
Orthopedic hardware 3 (17)
Othera 4 (22)
Evidence of any contact with dog in medical record 4 (6)
Medical services












Other, steriled 4 (5)
aPeripheral catheter, left ventricular assist device, insulin pump, and tracheostomy tube.
bCardiology, gynecology, infectious disease, neurology, podiatry, pulmonary, and surgery.
cLower respiratory (n  9), sinus drainage (n  7), and ear drainage (n  1).
dBone and synovial ﬂuid.
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patients with S. aureus and 42% with CNS (21). Common comorbidities for SIG infection
included diabetes (n  18 [29%]) and immunosuppression (n  17 [27%]), and medical
hardware was reported to be present in 18 cases (29%) (Table 1). A review of medical
records found evidence of any contact with a dog in only 4 patients (6%). Patients with
SIG infection were most commonly managed by dermatology (n  14 [23%]) or
otolaryngology (n  11 [18%]). The primary source of specimens was wounds (n  37
[46%]), in comparison to 17% of S. aureus and 12% of CNS isolates reported in wound
cultures during the same time period (P 0.001). Respiratory specimens were the other
major source (n  17 [21%]) of SIG isolates, compared to 17% of S. aureus and 0.2% of
CNS isolates (P  0.001) (21). The remainder of the SIG isolates were obtained from
sterile specimens, including tissues (n 13 [16%]), bone and synovial ﬂuid (n 4 [5%]),
and blood (n  10 [12%]). Notably, SIG isolates were obtained from the blood of 7 (9%)
unique patients.
The incidence of SIG infections was compared to the months in which SIG isolates
were obtained (Fig. 1). The majority of SIG isolates were reported between the months
of July and September, while the incidence was lowest in the months of January to
March. This trend tracked with the average temperature for the area (Fig. 1). Linear
regression analysis showed a statistically signiﬁcant (P 0.01) although relatively minor
increase in the monthly incidence of SIG infection with increasing average monthly
temperature (0.05 with each increase of 1°C).
Microbiologic characteristics of human clinical isolates of SIG. Specimen Gram
stains were performed and reported on 70 of 81 specimens. Of these, 34 specimens
(49%) had no polymorphonuclear leukocytes (PMNs) present, 21 specimens (30%) had
rare to few PMNs (10 present per low-power ﬁeld), and 15 specimens (21%) had
moderate to abundant PMNs (10 present per low-power ﬁeld) (Table 2). Gram-
positive cocci were noted on 42 (60%) of the Gram stains and were associated with
PMNs in 22 (31%) Gram-stained specimens (Table 2).
The majority of SIG isolates exhibited beta-hemolysis on blood agar plates (78/81
[96%]). Isolates were identiﬁed using phenotypic methods (29/81 [36%]) prior to the
implementation of MALDI-TOF MS, which was used for identiﬁcation of the majority of
isolates (52/81 [64%]). Notably, errors in the initial identiﬁcation of SIG isolates were
reported in patient charts in 6 out of 29 (21%) instances using phenotypic methods,
while no errors in identiﬁcation occurred with the use of MALDI-TOF MS. Biochemical
testing using the PYR test was used to differentiate SIG isolates from other Staphylo-
coccus species. The result was positive in 26 of 27 isolates (96%) tested. Staphylococcus
FIG 1 Comparison of average seasonal temperature (degrees Celsius) and incidence of SIG infection. The numbers
of SIG isolates obtained quarterly from 2013 to 2015 (gray bars) are compared to the average temperature for the
area (red line) in the same time period.
Yarbrough et al. Journal of Clinical Microbiology
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latex agglutination testing was performed on 39 isolates, with results recorded as
positive, negative, or questionable for 6 (15%), 19 (47.5%), and 15 (37.5%) isolates,
respectively.
The majority of SIG isolates were obtained from polymicrobial cultures (53/81
[65%]). A SIG isolate was accompanied by one other organism in 15 (19%) cultures,
while 28 (35%) isolates were obtained from mixed cultures (3 organisms) (Table 3). In
polymicrobial cultures, the organisms most commonly isolated from SIG cultures
included CNS species (9/53 [17%]), Streptococcus agalactiae (4/53 [8%]), and Escherichia
coli (4/53 [8%]). Both S. aureus and Staphylococcus lugdunensis were recovered from 3
of 53 (6%) polymicrobial cultures (Table 3).
Antimicrobial susceptibility proﬁles of SIG. The susceptibilities of SIG isolates to
various antimicrobial agents were compared to the institutional S. aureus antibiogram
from the same time period (Table 4). While there was no difference in susceptibility to
clindamycin (70% susceptible for both SIG isolates and S. aureus, P  1.0), there were
signiﬁcant differences in the percentages of SIG isolates that were susceptible com-
pared to S. aureus for doxycycline (74% versus 97%, respectively; P  0.001),
trimethoprim-sulfamethoxazole (65% versus 97%, respectively; P  0.001), and cipro-
ﬂoxacin (78% versus 59%, respectively; P  0.01). Of the SIG isolates, 12 (15%) isolates
exhibited MR. Among the MR isolates, 25% and 8% tested were susceptible to clinda-
mycin and trimethoprim-sulfamethoxazole, respectively. Ten MR isolates were tested
for doxycycline and ciproﬂoxacin, of which 50% and 0% were susceptible, respectively.
In isolates that were tested using oxacillin as a surrogate for MR prediction in SIG
isolates (n  54), 81% were methicillin susceptible. In comparison, S. aureus isolates
tested within the same time period (n 1,604) were 50% susceptible using cefoxitin as
a surrogate for MR (Table 4). Both cefoxitin and oxacillin disk zone sizes were recorded
for 34 SIG isolates. A comparison of the zones found no correlation (R2 value  0.3615)
between the cefoxitin and oxacillin test results (Fig. 2). Seven of 34 (21%) isolates tested
by both cefoxitin and oxacillin disk diffusion tests exhibited MR using oxacillin as a
surrogate. Using either the S. aureus or CNS breakpoints derived from the CLSI
M100-S27 standards (15), all 7 of the MR SIG isolates would have been falsely predicted
as susceptible if cefoxitin were used as a surrogate for methicillin susceptibility. Two of
TABLE 2 Culture characteristics






Gram-positive cocci present 42 (60)
PMNs and Gram-positive cocci present 22 (31)
eta-hemolysis on blood agar 78 (96)
Method of SIG identiﬁcation
Phenotypic 29 (36)
Errors in initial identiﬁcation 6 (21)
MALDI-TOF MSa 52 (64)








aMatrix-assisted laser desorption ionization–time of ﬂight mass spectrometry with Bruker Biotyper.
bPyrrolidonyl arylamidase.
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10 SIG isolates that were tested for PBP2a by rapid immunoassay were positive. The
PBP2a result correlated with 7 of 7 isolates tested by oxacillin disk diffusion and 3 of 3
tested by cefoxitin disk diffusion.
DISCUSSION
SIG isolates are increasingly recognized as a cause of human infection (1, 4, 5, 7). Our
retrospective review of all SIG isolates obtained in our clinical microbiology laboratory
during a 3-year period found that SIG isolates are most commonly recovered from
wounds and respiratory specimens. Risk factors associated with SIG infection included
TABLE 3 Composition of SIG cultures
SIG culture characteristic No. (%)
Monomicrobial cultures 28 (35)
Polymicrobial cultures 53 (65)













Streptococcus anginosus group 1
Streptococcus pneumoniae 1








Acinetobacter calcoaceticus-A. baumannii complex 2
Stenotrophomonas maltophilia 1
Other Gram-negative bacilli 2
Anaerobes





TABLE 4 Comparison of antibiotic susceptibility of SIG and S. aureus isolatesa
Antibiotic
Susceptible (%)
P valueSIG S. aureusb
Oxacillin (surrogate)c 81 NA
Cefoxitin (surrogate) NA 50
Clindamycin 70 70 1.0
Doxycycline 74 97 0.001
Trimethoprim-sulfamethoxazole 65 97 0.001
Ciproﬂoxacin 78 59 0.01
aS. aureus represents data from a 2015 S. aureus antibiogram. NA, not available.
bInterpretive criteria from CLSI, M100, 25th edition (38).
cn  54 (67%) isolates for which an oxacillin result was available.
Yarbrough et al. Journal of Clinical Microbiology
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diabetes, immunosuppression, and the presence of hardware. A previous analysis of 24
human cases of SIG infection found that 92.1% of cases were related to contact with
dogs at the time of infection (4). However, a review of the medical record in our study
found an association with dogs in less than 7% of cases, with only one case of an injury
from a dog bite. This is not to say that the patients in our cohort did not have contact
with dogs; rather, animal exposure was not documented often in the medical record.
Our ﬁndings are consistent with the results of a previous study in which animal contact
was noted in less than 10% of the clinical documentation of SIG cases (1). In spite of
this, dogs are potential sources for human infection, as both dog-to-dog and dog-to-
human transmission have been described (22, 23). Interestingly, we noted a trend
toward increased incidence of SIG infection reported in warmer months and less
occurrence in the colder months. This is consistent with a higher likelihood of outdoor
activities and possible animal exposure.
Given the polymicrobial makeup of the majority of cases in our study, the signiﬁ-
cance of SIG isolation may be questionable. However, the presence of PMNs and
Gram-positive cocci was noted in the majority of isolates in which a Gram stain was
available, supporting the idea that SIG isolates are important contributors to infection
in many of these instances. In addition, SIG isolates were associated with 8 cases of
invasive disease in our study, including joint infection and bacteremia. The majority of
cases of bloodstream infections occurred in immunosuppressed patients with cathe-
ters. However, in one diabetic patient without hardware, SIG bacteria were isolated
from neck abscess, joint ﬂuid, and blood specimens. In this case, the presence of three
dogs in the patient’s household was detailed in the medical record.
The use of MALDI-TOF MS for bacterial species identiﬁcation has led to the emer-
gence of several microorganisms once thought to be uncommon human pathogens
(24–27). Phenotypic characteristics of SIG, including the presence of beta-hemolysis on
blood agar and a positive coagulase reaction, may lead to the mischaracterization of
FIG 2 Correlation of oxacillin and cefoxitin zone sizes (in millimeters) for a subset of SIG isolates (n  34) tested
by both cefoxitin and oxacillin disk diffusion. The lines represent susceptibility breakpoints for coagulase-negative
Staphylococcus (CNS, dotted line), S. aureus (dashed line), and SIG (solid line), as described in CLSI standards (17).
Seven MR isolates were mischaracterized as methicillin susceptible by cefoxitin (lower right section of graph). Small
points indicate 1 isolate, medium-sized points represent 2 isolates, and the largest point represents 3 isolates.
Analysis of Staphylococcus intermedius Clinical Isolates Journal of Clinical Microbiology
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SIG as S. aureus in human clinical isolates (7, 8). This is supported by our data, in which
six errors were made in the initial identiﬁcation of SIG isolates using phenotypic
methods, compared to no errors in reporting the identiﬁcation after implementation of
MALDI-TOF MS. Notably, no errors were the result of a false identiﬁcation by the Vitek 2
system. A comparison of the local S. aureus antibiogram found that SIG isolates are
signiﬁcantly more likely to be resistant to doxycycline and trimethoprim-sulfamethoxazole,
which could serve as an additional unique identifying characteristic of SIG isolates of which
laboratories should be aware. While this pattern of multidrug resistance was most strongly
associated with MR SIG isolates, this resistance proﬁle was signiﬁcantly different from S.
aureus among methicillin-susceptible SIG isolates as well. Additionally, the PYR test is a
useful biochemical test for the differentiation of SIG from S. aureus and most other
Staphylococcus species (with S. lugdunensis being a notable exception) (28). One isolate
in our study was negative by manual PYR testing. This could have been due to a
technical error during PYR testing, as the isolate was identiﬁed as SIG by Vitek 2 and
MALDI-TOF MS.
Studies of both human and veterinary isolates suggest that globally, SIG isolates are
genetically heterogeneous and have arisen from multiple recombination events (29,
30). The spread of MR in SIG isolates is postulated to occur via gene transfer rather than
clonal spread, which is supported by the ﬁnding that MR occurred in diverse SIG
populations (29). Several studies have noted that MR in veterinary isolates is associated
with prior antimicrobial treatment (29, 31, 32).
With the rising incidence of MR, correct identiﬁcation of SIG is essential to ensure
accurate prediction of MR in SIG isolates. Like S. aureus, MR in SIG isolates is usually
mediated by the production of PBP2a encoded by mecA (11). Unlike S. aureus, in which
disk diffusion testing using cefoxitin is the surrogate for MR, disk diffusion testing with
oxacillin is the indicator of MR for SIG isolates (15). This is supported by our data, which
found no correlation between oxacillin and cefoxitin zone sizes for a proportion of SIG
isolates that were tested using both agents. Twelve isolates were methicillin resistant
in our study, and this was almost always accompanied by multidrug resistance to other
antibiotics, including clindamycin, ciproﬂoxacin, and doxycycline. Methicillin resistance
in our isolates may have been underreported, as 13 susceptible isolates were tested
using only cefoxitin disk diffusion testing prior to the updated recommendation to use
oxacillin. In the absence of oxacillin disk diffusion testing, PBP2a may be an acceptable
substitute to predict methicillin resistance (11, 14). Two recent studies that evaluated
the performance of a rapid immunochromatographic assay found that the method was
able to detect methicillin resistance with 100% sensitivity and speciﬁcity, albeit some
isolates required induction by cefoxitin (11, 14). Notably, PBP2a testing was performed
for 3 of the 13 susceptible isolates in our study, all with a negative result.
In the past, the isolation of Staphylococcus species that were not S. aureus were often
disregarded as contaminants, and species-level identiﬁcation of many staphylococci
required cumbersome or time-consuming methods. However, advances in bacterial
identiﬁcation methods have facilitated species-level identiﬁcation of many Staphylo-
coccus species, which in turn has revealed the contribution of many CNS species to
clinically signiﬁcant disease (33–35). Furthermore, the importance of species-level
identiﬁcation of Staphylococcus species may be necessary to accurately predict MR, as
in the case of the SIG and Staphylococcus schleiferi (36). It is likely that as our
understanding of the importance of many Staphylococcus species continues to im-
prove, the necessity for additional species-speciﬁc breakpoints may be necessary.
To our knowledge, this is the largest and most comprehensive study of the clinical
and microbiological characteristics of human clinical infection with the SIG to date. One
limitation of this study is that multiple identiﬁcation methods were used over the
course of the study, and the methods used could reliably resolve SIG isolates only to the
group level. While this is sufﬁcient for clinical management, we were unable to
determine if certain members of the group were more or less common in human
infection than others. Additionally, it is possible that some SIG isolates were not
detected by the laboratory in polymicrobial cultures or as a result of errors in the
Yarbrough et al. Journal of Clinical Microbiology
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identiﬁcation of SIG isolates using phenotypic methods. Due to the retrospective study
design, the colony morphology, Gram stain descriptions, biochemical testing, and
antimicrobial agents tested were limited to what was described in the standard-of-care
culture record. Finally, this is a single-center study, and it is unknown how these
ﬁndings might apply to other settings.
In conclusion, SIG bacteria are an underappreciated cause of human infection,
especially skin and soft tissue infections, bacteremia, and respiratory infections. As dogs
and other animals are potential reservoirs for MR SIG isolates, knowledge of animal
exposure in patients with SIG isolates growing in culture is helpful to determine clinical
signiﬁcance and prevent further transmission. Correct species-level identiﬁcation is
essential for an optimal interpretation of antimicrobial susceptibility testing results and
subsequent antimicrobial therapy. While SIG isolates can be reliably identiﬁed by
MALDI-TOF MS, clinical microbiology laboratories that rely on phenotypic methods of
identiﬁcation should be aware of the microbiological characteristics of this organism
that differentiate it from other Staphylococcus species.
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